Dermatology reimbursement alerts

This active final LCD from Wellpoint Federal governs coverage criteria for Incision and Drainage (I&D) of abscesses involving skin, subcutaneous tissue, and accessory structures, effective April 1, 20

Dupixent (dupilumab) is an injectable interleukin-4 receptor alpha antagonist approved for subcutaneous administration, placing it on the Part B billing pathway for physician-administered claims. Bill

Ilumya (tildrakizumab-asmn) is an injectable interleukin-23 antagonist approved for plaque psoriasis, administered via subcutaneous injection in a physician office or clinical setting, supporting Part

Ustekinumab (Stelara) is an injectable interleukin-12/23 antagonist approved via BLA125261, administered by injection and billed under Medicare Part B. As an injectable biologic administered in a phys

Elocon (mometasone furoate) is a topical corticosteroid cream approved under NDA019625, billing through Medicare Part D as a self-administered topical medication. As a long-established brand with exte

Elocon (mometasone furoate) Lotion is a topical corticosteroid approved under NDA019796, administered via the topical route, placing it squarely in the Part D billing pathway as a self-administered ou

Elocon (mometasone furoate) is a topical corticosteroid ointment approved in 1987, administered topically and billed under Medicare Part D as a self-administered drug. As a long-established branded to

ZORYVE (roflumilast) 0.3% cream was approved by the FDA on July 29, 2022, as a topical phosphodiesterase 4 inhibitor indicated for plaque psoriasis. As a topical cream, this product follows the Part D

Anzupgo (delgocitinib) is a topical JAK inhibitor cream approved as a new molecular entity, with a clear Part D billing pathway as a self-administered topical drug. It will be dispensed through retail

Cibinqo (abrocitinib), an oral Janus Kinase Inhibitor approved for atopic dermatitis, follows a Part D billing pathway as an oral tablet dispensed through retail or specialty pharmacy. Because this is

Litfulo (ritlecitinib) is an oral capsule approved via NDA215830 and follows a Part D billing pathway, meaning it is dispensed through retail or specialty pharmacies rather than administered in a clin

Sotyktu (deucravacitinib) is an oral tablet approved as a new molecular entity, placing it squarely in the Medicare Part D billing pathway as a self-administered drug. As a branded oral specialty medi

Leqselvi (deuruxolitinib phosphate) was approved by the FDA on July 25, 2024, as an oral tablet, placing it squarely in the Medicare Part D billing pathway as a self-administered drug. As a new molecu

Opzelura (ruxolitinib) cream received FDA approval via NDA215309 as a topical formulation, placing it firmly in the Medicare Part D billing pathway as a self-administered drug. As a topical cream, it

SKYRIZI (risankizumab-rzaa) is an injectable drug approved for use under Medicare Part B, likely leading to the assignment of a new J-code for billing purposes. As an orphan drug in the interleukin-23

SKYRIZI (Risankizumab-rzaa), being an injectable drug approved under the BLA, is likely to be assigned a J-code for Medicare billing. Given its classification as an orphan drug and its high cost, pass

CETIRIZINE HYDROCHLORIDE, marketed as ZYRTEC HIVES, is an oral drug and will be billed under Medicare Part D. Given that it is not an injectable drug, no J-code will be assigned, and typical reimburse

As ABSORICA (isotretinoin) is an oral drug, it will be billed under Medicare Part D. Given that it is a medication used for severe acne, prescribers should consider any prior authorizations or step th

EBGLYSS (LBRIKIZUMAB-LBKZ) will be billed under Part B as it is an injectable drug. Billing teams should confirm the specifics of the J-code upon the release of the FDA label.

The proposed Local Coverage Determination (LCD) for Superficial Radiation Therapy (SRT) will impact billing by potentially increasing reimbursement for treatments of nonmelanoma skin cancers. It aims

The proposed Local Coverage Determination (LCD) for Superficial Radiation Therapy (SRT) could significantly influence reimbursement levels for procedures related to Nonmelanoma Skin Cancers. Providers

The proposed LCD for Superficial Radiation Therapy (SRT) for Nonmelanoma Skin Cancers will likely expand coverage options, promoting more access to this treatment modality. This could positively impac

The proposed LCD for Superficial Radiation Therapy (SRT) may impact billing by clarifying coverage terms for treatment of Nonmelanoma Skin Cancers (NMSC). This requires billing team review

The proposed LCD for Superficial Radiation Therapy (SRT) will likely supports compliance with updated rates options for providers treating Nonmelanoma Skin Cancers (NMSC). This inclusion may lead to increased utilizat

The upcoming LCD for Melanoma Risk Stratification may significantly impact billing practices for providers conducting molecular testing. It sets clear guidelines for coverage, ensuring appropriate rei

The introduction of the MolDX Melanoma Risk Stratification Molecular Testing is expected to enhance precision in melanoma diagnostics, potentially leading to more tailored treatment plans. Providers s

The new Local Coverage Determination (LCD) for the removal of benign skin lesions by CGS may impact billing practices in dermatology, leading to increased scrutiny on claims for these procedures. Prov

The recent LCD on Wound and Ulcer Care may lead to supports compliance with updated rates processes, particularly for claims related to wound management. Proper documentation and adherence to the outlined

The introduction of the new LCD for Plastic Surgery by Noridian effective October 16, 2025, may significantly impact billing processes, affecting reimbursement rates and procedures allowable under Med

The introduction of Mohs Micrographic Surgery (MMS) by Noridian will enhance compliance updates for dermatology practices. This update is expected to improve reimbursement rates and streamline the

The new LCD for benign skin lesion removal may alter billing practices, particularly for cases excluding actinic keratosis and Mohs surgery. Providers should be aware of potential changes in reimburse

The new LCD from Noridian introduces updated guidelines for plastic surgery billing, which may affect reimbursement rates and claims processing. Providers should review the changes to ensure complianc

The implementation of the LCD for the removal of benign and malignant skin lesions by Palmetto GBA may affect billing practices starting from October 23, 2025. Providers will need to ensure compliance

The upcoming Local Coverage Determination (LCD) on the removal of benign skin lesions will clarify billing guidelines, potentially impacting reimbursement patterns for dermatology services. Providers

The Noridian LCD for Mohs Micrographic Surgery outlines specific billing requirements that could affect reimbursements if not followed accurately. Adhering to these guidelines is crucial for ensuring

The LCD for benign skin lesion removal may lead to an increase in denied claims if providers do not adhere strictly to the guidelines excluding actinic keratosis and Mohs procedures. Ensuring proper d

The new LCD from Noridian outlines guidelines for MolDX testing in cutaneous squamous cell carcinoma, which could impact reimbursement practices for genetic testing procedures. Billing for these servi

The introduction of the MolDX for the diagnosis of cutaneous melanoma may significantly impact billing practices for pathology services in dermatology. Providers may need to adapt to new HCPCS and ICD

The implementation of the new LCD for molecular biomarker testing in cutaneous squamous cell carcinoma may lead to supports compliance with updated rates, potentially impacting overall billin

The implementation of the MolDX: Pigmented Lesion Assay may significantly impact billing practices, as it introduces specific coding requirements that must be adhered to in order to ensure appropriate

The implementation of the MolDX: Pigmented Lesion Assay effective June 20, 2024, may introduce new billing procedures for providers. This could lead to changes in reimbursement patterns and necessitat

The new Local Coverage Determination (LCD) for Superficial Radiation Therapy (SRT) will provide clearer guidelines for billing related to Nonmelanoma Skin Cancers (NMSC). Effective from March 1, 2026,

The new local coverage determination (LCD) for Superficial Radiation Therapy could impact reimbursement for treatments of nonmelanoma skin cancers starting March 1, 2026. Facilities should prepare for

The implementation of Superficial Radiation Therapy (SRT) for Nonmelanoma Skin Cancers (NMSC) requires billing team review. Effective from March 1, 202

The introduction of the LCD for Superficial Radiation Therapy (SRT) will positively influence billing by ensuring clear guidelines for reimbursement related to Nonmelanoma Skin Cancers (NMSC). Provide

The new LCD on Superficial Radiation Therapy for Nonmelanoma Skin Cancers may lead to increased compliance updates for providers offering this treatment. However, it is essential to ensure proper d

The MolDX Pigmented Lesion Assay will have a significant impact on billing practices starting April 30, 2026. Providers must ensure they are familiar with the associated HCPCS and ICD-10 codes to opti

The final LCD L34195 relates to Mohs Micrographic Surgery and is now active. Providers in Kentucky and Ohio should ensure compliance with this policy effective May 7, 2026, regarding billing under Par

This LCD covers guidelines for billing cosmetic and reconstructive surgery services under Medicare. It affects both Part A and Part B claims, indicating specific criteria that must be met for procedur

Tremfya (Guselkumab) is an injectable drug that will likely be assigned a J-code for Medicare billing. As a Part B candidate, it may also be subject to ASP+6% reimbursement rates. Providers should be